for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Hypera SA

HYPE3.SA

Latest Trade

33.20BRL

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

24.56

 - 

33.93

As of on the Bolsa de Valores do Estado de Sao Paulo ∙ Minimum 15 minute delay

Pricing

Previous Close
33.20
Open
--
Volume
--
3M AVG Volume
35.11
Today's High
--
Today's Low
--
52 Week High
33.93
52 Week Low
24.56
Shares Out (MIL)
630.81
Market Cap (MIL)
20,737.41
Forward P/E
17.34
Dividend (Yield %)
2.75

Next Event

Q3 2019 Hypera SA Earnings Release

Latest Developments

More

Ontex completes acquisition of personal hygiene business of Hypermarcas

Ontex agrees to buy personal hygiene business of Hypermarcas

Hypermarcas SA to propose dividend payment

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Hypera SA

Hypera SA, formerly Hypermarcas SA, is a Brazil-based company engaged in the pharmaceuticals sector. The Company’s major business units include Branded Prescription, Consumer Health and Branded Generics. Branded Prescription is present in the main therapeutic classes in Brazil and it operates in the Primary Care segment under the umbrella brand Mantecorp Farmasa. The Branded Prescription unit also acts as Mantecorp Skincare in dermocosmetics, with products recommended by dermatologists. Consumer Health offers non-prescription drugs, with brands such as Apracur, Benegrip, Coristina d, Engov, Epocler and Estomazil, among others. The Consumer Health unit also operates in nutritionals and vitamin supplements, with brands such as Tamarine, Vitasay, Biotonico Fontoura and Zero-Cal. Branded Generics operates under the Neo Quimica brand.

Industry

Biotechnology & Drugs

Contact Info

R Nova Cidade. 404

+55.11.36274200

http://www.hyperapharma.com.br/

Executive Leadership

Luiz Eduardo Violland

Chairman of the Board

Claudio Bergamo dos Santos

Chief Executive Officer, Member of the Executive Board

Martim Prado Mattos

Chief Financial Officer, Chief Controllership Officer, Member of the Executive Board

Vivian Karina Trujillo Angiolucci

Chief Operating Officer, Member of the Executive Board

Breno Toledo Pires de Oliveira

Investor Relations Officer, Member of the Executive Board

Key Stats

2.53 mean rating - 15 analysts
Sell
Hold
Buy
Revenue (MM, BRL)

2016

3.3K

2017

3.6K

2018

3.7K

2019(E)

3.4K
EPS (BRL)

2016

1.067

2017

1.760

2018

1.790

2019(E)

1.892
Price To Earnings (TTM)
17.23
Price To Sales (TTM)
6.41
Price To Book (MRQ)
2.42
Price To Cash Flow (TTM)
15.57
Total Debt To Equity (MRQ)
6.51
LT Debt To Equity (MRQ)
5.09
Return on Investment (TTM)
13.47
Return on Equity (TTM)
12.01

Latest News

Brazil's Hypera controlling shareholder in plea deal talks-report

The controlling shareholder of Brazil's Hypera SA is in initial talks about a plea deal, Brazil's Valor Economico newspaper reported on Wednesday, as the pharmaceutical company continues an internal probe into alleged corruption.

Brazil's Hypera reports Q2 net profit of 278.8 mln reais

Quarterly profit at Hypera SA , Brazil's largest listed producer of over-the-counter medicine, rose 22.3 percent on a yearly basis in the second quarter as revenues increased more than 10 percent due to higher overall sales.

Brazil's Hypera appoints committee to investigate after police raid

Brazilian pharmaceuticals company Hypera SA said on Wednesday that its board had appointed an independent committee to investigate alleged corruption by former executives.

Brazil's Hypera in talks for leniency deal, could pay $540 mln fine -paper

Brazilian pharmaceutical company Hypera SA is in talks to agree to a leniency deal with prosecutors that could include a 2 billion reais ($540 million) fine, newspaper Valor Economico reported on Thursday, an agreement that Hypera denied.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up